Latest revenue
$5.5M
as of 2026-03-31
Latest net income
$-2.6M
as of 2026-03-31
Net margin
-46.8%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $3.8M
- Enterprise value
- $3.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $4.00
- 52-wk low
- $0.24
- Beta
- —
- Shares out
- 14.9M
5-year trend
What this company does
PART I Item 1. Business Unless the context otherwise requires, for purposes of this section, the terms “we,” “us,” “the Company” or “Synergy” refer to Synergy CHC Corp. Our Company We are a provider of consumer health care, beauty, and lifestyle products. Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement (this study was performed independently and is not related to any U.S. Food and Drug Administration (“FDA”) -approved investigational new drug (IND) application) that has been shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products to help…
AI summary unavailable — showing raw filing excerpt
Generated from SNYR's filing dated 2026-04-01
Key risks
Item 1A. Risk Factors An investment in our common stock involves a high degree of risk. You should carefully consider the following risks and all of the other information contained in this Annual Report before deciding whether to invest in our common stock. If any of the following risks are realized, our business, financial condition, results of operations and cash flows could be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose all or part of your investment in our common stock. Additional risks of which we are not presently aware or that we currently believe are immaterial may also harm our business, results of…
AI summary unavailable — showing raw filing excerpt
Generated from SNYR's filing dated 2026-04-01
Profitability
Gross margin
66.8%
1.5%Operating margin
-27.8%
267.2%Net margin
-40.6%
765.9%Return on equity
74.2%
1053.5%Return on assets
-121.4%
1033.8%Leverage
Debt / equity
-1.61×
0.8%Long-term debt / equity
-1.51×
451.7%Debt / assets
263.6%
1.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $5.5M | -32.8% | $-2.6M | -393.2% | -46.8% |
Q4 2025 2025-12-31 | $6.1M | -40.9% | $-14.8M | -14121.4% | -244.3% |
Q3 2025 2025-09-30 | $8.0M | +12.4% | $125.3K | -84.0% | 1.6% |
Q2 2025 2025-06-30 | $8.1M | +1.4% | $1.5M | +124.9% | 18.1% |
Q1 2025 2025-03-31 | $8.2M | -13.2% | $876.3K | +50.9% | 10.7% |
Q4 2024 2024-12-31 | $10.3M | — | $105.7K | — | 1.0% |
Q3 2024 2024-09-30 | $7.1M | -34.1% | $783.6K | -39.0% | 11.0% |
Q2 2024 2024-06-30 | $8.0M | — | $655.2K | — | 8.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Medicinal Chemicals & Botanical Products · SIC 2833
Your notes
Keep private notes on SNYR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$109.4K
Insider selling
$0
Net activity
+$109.4K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns SNYR
Institutional value
$1.4M
Total shares held
1.1M
Distinct holders
9
-2 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | HEARTLAND ADVISORS INC | 550.0K | $709.5K | +0 (+0.0%) | No change |
| 2 | SANDERS MORRIS HARRIS LLC | 415.5K | $535.9K | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 89.8K | $115.8K | — | New |
| 4 | VANGUARD FIDUCIARY TRUST CO | 23.1K | $29.9K | — | New |
| 5 | Warberg Asset Management LLC | 10.2K | $13.2K | -3.5K (-25.3%) | Trimmed |
| 6 | Williams & Novak, LLC | 11.9K | $12.2K | — | New |
| 7 | UBS Group AG | 900 | $1.2K | -298 (-24.9%) | Trimmed |
| 8 | Clearstead Advisors, LLC | 109 | $141 | +60 (+122.4%) | Added |
| 9 | CITIGROUP INC | 1 | $1 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once SNYR's latest filing finishes processing.